Measures effectiveness of current migraine treatment plan.
Audience: PRACTITIONER
Published by EVAL Foundation
Revision 1 · Published April 23, 2024
Inadequate acute episodic migraine (EM) treatment efficacy has been associated with an increased risk of new-onset chronic migraine (CM) over the course of 1 year (Lipton et al., 2015). It is suggested that improving acute treatment outcomes might prevent new-onset CM. The Migraine Treatment Optimization Questionnaire (mTOQ-4) is a validated 4-item questionnaire that assesses acute treatment efficacy. The original validation work was conducted on the 19-item mTOQ but subsequent derivations have been studied, such as the mTOQ-4. Items in the mTOQ-4 have been shown to have test-retest reliability and validity, but the TOQ-4 has not been validated as a stand-alone measure.
.The Migraine Treatment Optimization Questionnaire (mTOQ-4) is a validated 4-item questionnaire that assesses acute treatment efficacy.
Scoring & Recommendations
The 4 questions will answer with one of the following:
| Answer | Points |
| Never or rarely | 0 |
| Less tan half the time | 1 |
| Half the time or greater | 2 |
The mTOQ-4 score is calculated by the addition of the selected points in each of the 4 questions and the following results display:
| mTOQ-4 Score | Treatment Effectiveness |
| 0 | Very poor treatment efficacy |
| 1-5 | Poor treatment efficacy |
| 6-7 | Moderate treatment efficacy |
| 8 | Maximum treatment efficacy |
Management
Higher scores correlate to better treatment efficacy and symptom control. Consider modifying therapy if scores are low.
.Current: Revision 1
About this evaluation